On June 3rd, the €5bn Scaleup Europe Fund was formally launched at the EIC – European Innovation Council Summit in Brussels.
While the fund is not exclusively focused on biotech, it could be highly relevant for European life sciences companies looking to scale. The initiative is designed to support strategic technology businesses, including biotech and medical technologies, by addressing the late-stage funding gap that often limits European companies’ ability to grow globally.

The appointment of Swedish investment group EQT Group as preferred adviser/fund manager also suggests a strong growth-equity focus.

For biotech companies, the key question will be whether this becomes a meaningful route to larger-scale European funding, helping promising science move from innovation into clinical development, commercialisation and global growth.